A New Diagnostic Standard for Rare Disease
Helix has introduced Whole Exome+ Sequencing, a diagnostic tool designed for patients facing unexplained neurological symptoms, developmental delays, and rare genetic conditions. The platform integrates exome, mitochondrial, and chromosomal analysis into a single order. This approach aims to reduce the diagnostic timeframes that often plague families searching for answers.
Modern clinical guidelines now prioritize exome and genome sequencing for children with undiagnosed conditions. Organizations such as the American College of Medical Genetics and the American Academy of Pediatrics recognize this shift. Helix designed the WES+ test to meet these updated recommendations while replacing multiple, fragmented tests with a more efficient workflow.
Integrating Data for Clinical Clarity
Diagnostic precision relies on the quality of data provided at the start. The WES+ system captures data across 99% of clinically relevant regions. It also includes high-resolution chromosomal copy number analysis through a digital karyotype. By providing this digital view, clinicians may find they no longer need a separate chromosomal microarray, streamlining the initial evaluation process.
Integrating mitochondrial genome analysis as a standard component is a significant change. In many labs, this testing is an add-on or a separate order entirely. By including it in the WES+ test, Helix gives providers broader visibility into the underlying genetic drivers of a patient’s health, supporting more accurate and timely care from the first clinical visit.
The Sequence Once, Query Often Approach
Helix utilizes its proprietary Sequence Once, Query Often model to manage genomic information. This strategy transforms a patient's genetic data into a permanent clinical asset rather than a temporary test result. Because clinical science changes, the company allows for one complimentary reanalysis of the data per year upon provider request.
This re-querying capability allows providers to check existing sequence data against emerging gene-disease associations. It ensures that patients who were previously undiagnosed can benefit from new scientific discoveries without needing a fresh sample collection. This model keeps the focus on patient outcomes by maximizing the utility of the original test.
Implementation and Future Access
Healthcare providers can order WES+ through the established Helix portal or integrated electronic health record systems. The test supports proband-only, duo, and trio configurations, allowing clinicians to tailor the analysis to the specific family history and clinical presentation. Helix works with national and regional insurance plans to manage costs and offers financial assistance programs for families who need support.
As health systems build out their EHR integrations, the availability of this test will continue to spread. This launch marks a move toward embedding comprehensive genomic evaluation into the standard clinical workflow. The goal is to minimize the years of uncertainty that often follow initial symptom onset for patients living with rare conditions.